No current GLP-1 label lists Parkinson's disease as an approved use, so prescribing one for it would be off-label. Exenatide-PD3 (Exenatide): Over 96 weeks, movement scores worsened 5.7 points on exenatide against 4.5 on placebo. The authors found no evidence for it as a disease-modifying treatment. ClinicalTrials.gov lists 9 trials of these medicines on it: 1 with posted results and 0 recruiting now.
Read from the registry and PubMed every day. The newest update here is May 6, 2026.
Each read in the paper's abstract on Nov 6, 2026. Trials differ in who took part and how long they ran.
Exenatide · 194 people · No clear benefit · Placebo-controlled randomized trial
Over 96 weeks, movement scores worsened 5.7 points on exenatide against 4.5 on placebo. The authors found no evidence for it as a disease-modifying treatment.
A trial counts when the registry's conditions or title name this, and some study a related question, such as insulin sensitivity in people with the condition. A registered trial shows a question being asked, not that the answer is yes.
| Medicine | Trials | Posted results | Recruiting |
|---|---|---|---|
| Exenatide | 7 | 0 | 0 |
| Liraglutide | 1 | 1 | 0 |
| Semaglutide | 1 | 0 | 0 |
Latest phases and largest trials first. Each result is the first primary outcome as its sponsor posted it to the registry, which is not peer review.
| Trial | Medicine | Phase | People | Result |
|---|---|---|---|---|
| NCT02953665Safety and Efficacy of Liraglutide in Parkinson's Disease | Liraglutide | Phase 2 | 63 | Change in Unified Parkinson's Disease Rating Scale (UPDRS Part III Motor Examination) During "OFF" Time From Baseline to the End of Double-Blind Maintenance Period (units on a scale), From Baseline (Week 0) to end of Maintenance Period (up to 54 weeks). Full Analysis Set (Liraglutide-treated Subjects): -2.3; Full Analysis Set (Placebo-treated Subjects): -5.0. |
Meta-analysis · Brain Behav · Apr 1, 2026 · Raza H et al. · cited by 1
Listed from Europe PMC as published, newest first. A listing here is not a judgement of a study's quality or a recommendation.
Exenatide-PD3 (Exenatide, 194 people): Over 96 weeks, movement scores worsened 5.7 points on exenatide against 4.5 on placebo. The authors found no evidence for it as a disease-modifying treatment.
Not in any current label we read. A prescriber can still use a medicine off-label, but insurance often limits coverage to approved uses, so ask your plan.
Exenatide, with 7 registered trials on it, then Liraglutide with 1. More trials do not mean better results: read what each posted.
None is recruiting on ClinicalTrials.gov now.